Client 1ST Advisory Group LLC Takes $614,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

Client 1ST Advisory Group LLC acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,122 shares of the medical research company’s stock, valued at approximately $614,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nordea Investment Management AB raised its stake in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the last quarter. Simplify Asset Management Inc. raised its position in shares of IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after acquiring an additional 3,894 shares during the last quarter. Versor Investments LP bought a new position in shares of IQVIA in the 3rd quarter worth $1,328,000. JPMorgan Chase & Co. grew its stake in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. Finally, CIBC Asset Management Inc increased its holdings in IQVIA by 3.3% in the third quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock valued at $62,501,000 after purchasing an additional 8,490 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Down 0.2 %

Shares of NYSE:IQV opened at $197.25 on Monday. The stock has a market capitalization of $35.80 billion, a PE ratio of 25.89, a price-to-earnings-growth ratio of 2.09 and a beta of 1.48. The company’s 50-day moving average price is $200.09 and its two-hundred day moving average price is $221.39. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73.

Analysts Set New Price Targets

IQV has been the subject of several analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Evercore ISI cut their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. The Goldman Sachs Group decreased their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, William Blair reiterated an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $255.82.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.